SUMMARY We studied the course of adjuvant arthritis in rats by measuring clinical, biochemical, and histological parameters on day 36 after induction (representing the secondary reaction) and on day 171, which is at the stage of permanent deformity. The effect of SR 41319, a new diphosphonate, was evaluated on days 36 and 171, after three weeks of treatment (days 14-35 inclusive). In the absence of treatment all the measured parameters were markedly abnormal on day 36, indicating the presence of lesions that were still evolving. On day 171 clinical parameters and the lesion histological index remained the same, whereas the biochemical parameters and disease activity histological index had returned to normal, indicating that the lesions at this stage although severe were not inflammatory and consequently not progressing. SR 41319 treatment reduced the severity and progression of the disease both on day 36 and on day 171. We conclude that SR 41319 may be a potentially useful drug for the treatment of rheumatoid arthritis.
Rheumatoid arthritis is a chronic inflammatory disease of joints resulting in cartilage and bone destruction by proliferating synovial tissue. As the evolution of the disease shows periods of exacerbation of inflammatory symptoms, the search for drugs to treat rheumatoid arthritis has been directed mostly against inflammation, leading to the introduction of non-steroidal anti-inflammatory drugs (NSAIDs). Clinical evidence, however, has shown that although NSAIDs are effective inhibitors of inflammatory symptoms, they do not influence the erosive process.' We speculated that new agents directed at the rheumatoid process itself might limit cartilage and bone erosion. To test such agents we have therefore developed a model of rat adjuvant arthritis which exhibits a prolonged phase of chronic inflammation associated with severe tissue injury (and bone remodelling), and in the present paper we describe the evolution of the disease over a period of nearly six months, while monitoring several clinical, biochemical, and histological parameters. This model has been used to assess the effects of a three-week treatment with a new potentially antiarthritic diphosphonate,2 SR 41319, (4chloro-phenyl) thio methylene diphosphonic acid.
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Materials and methods
ANIMALS
Seventy adult male COBS CD rats from Charles River (France) weighing 160±10 (SEM) g at the beginning of the experiment were used.
ARTHRITIS
Arthritis was induced by intradermal injection of 04 mg of heat killed, dried Mycobacterium tuberculosis (Difco Laboratories, Inc., Detroit, MI) in 0-05 ml of sterile paraffin oil into the base of the tail of 60 rats. Ten rats acted as controls. The day of adjuvant injection was designated day 0. Disease intensity was assessed 14 days after adjuvant inoculation by means of a polyarthritis index (PI:see below). In order to minimise the possibility of including animals with minimal transient disease only rats with a PI of 6 or more were included; these were randomly assigned to two groups of 14 Biochemical measurements were performed at the time of sacrifice: erythrocyte sedimentation rate was determined at two hours and plasma sulphydryl (SH) level was spectrophotometrically assessed with Ellman's reagent3 on blood collected over sodium citrate (1%) by abdominal aorta puncture. Simultaneously, the left hind paw of each rat was cut at the level of the tibiotarsal joint, ground in liquid nitrogen (freezer mill SPEX), and freeze dried; the amounts of prostaglandin E2 (PGE2) and I-Nacetylglucosaminidase activity (NAG) in this sample were measured by a radioimmunoassay with Pasteur antisera4 for PGE2 and a spectrophotometric assay with p-nitrophenyl-N-acetyl-f3-D-glucosaminide as substrate for NAG.5
STATISTICAL ANALYSIS
Student's t test was used to analyse all parameters except the polyarthritis index, the radiological score, and the histological indexes, which were analysed by the Kruskal-Wallis test.
Results
TIME COURSE OF ARTHRITIS UP TO DAY 171
Fig. la shows changes of PI for positive controls (group 1) during the observation period of 171 days after adjuvant injection. Arthritic rats showed a progressive increase of PI which peaked 24 days postadjuvant and slowly decreased thereafter but still remained high (about 7) at the end of the experiment. The kinetics of changes in paw volume were somewhat different, the maximum swelling occurring on day 43 and remaining at this high level throughout the experiment (Fig. lb) . These clinical changes were reflected in the grip strength: arthritic rats on day 35 and on day 170 were scarcely able to remain on the rotating rod (Table 1 ). The kinetics of changes in the biochemical parameters (Table 2) were quite different. The group.bmj.com on June 28, 2017 -Published by http://ard.bmj.com/ Downloaded from biochemical parameters in the treated group were significantly improved compared with controls on day 36 (Table 2) . As expected, the same pattern was observed in the x-ray and histological analyses (Figs  2 and 3) . On day 36 (Table 3 ) RI, LI, and DAI were significantly lower in the treated group than in the positive control group. On day 171 lesions were completely stabilised in both groups, but in SR 41319 treated rats they remained at a lower level, as assessed by both RI and LI (Table 3) .
Discussion
Chronic disease, such as human rheumatoid arthritis or rat adjuvant arthritis (AA), involves not only obvious signs of inflammation but also changes in various haematological and biochemical parameters.6 According to Billingham and If the fact that interleukin I has been detected in rheumatoid joint effusions25 and probably also in serum from patients with active rheumatoid arthritis26 is taken into account, this inhibitory effect of SR 41319 on the effects of interleukin I may at least partly explain its antiarthritic activity. 
